A Randomized, Open-Label, Phase 3 Study Evaluating Efficacy and Safety of Navitoclax in Combination with Ruxolitinib Versus Best Available Therapy in Subjects with Relapsed/Refractory Myelofibrosis (TRANSFORM-2).

  • Perkins, Andrew (Primary Chief Investigator (PCI))
  • Kennedy, Nola (Project Manager)
  • Hamad, Nada (Chief Investigator (CI))
  • Chuah, Hun (Chief Investigator (CI))
  • Arbelaez, Alejandro (Chief Investigator (CI))
  • Prasad, Ritam (Chief Investigator (CI))

Project: Research

Project Details

Effective start/end date12/10/2031/12/25


  • Blood diseases
  • Myelofibrosis
  • Clinical trial